Neoadjuvant GOLP in Intrahepatic Cholangiocarcinoma

To the Editor: In the ZSAB-neoGOLP trial, Shi et al. (March 5 issue) 1 found that neoadjuvant therapy with gemcitabine–oxaliplatin, lenvatinib, and the anti–programmed death 1 antibody toripalimab (GOLP regimen), followed by surgery and adjuvant capecitabine, led to significantly longer event-free survival than up-front surgery and adjuvant capecitabine (control) among patients with resectable high-risk intrahepatic cholangiocarcinoma. However, the median event-free survival that was observed in the control group (8.7 months) appears to be unexpectedly short. In the randomized BILCAP trial, which established adjuvant capecitabine as the standard care after resection of biliary tract cancers, including intrahepatic cholangiocarcinoma, the median recurrence-free survival . . .